FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
@fiercebiotech X フォロワー 102.9K最初の製品リリース:10年前
- 月間合計訪問数
- 879.4K
- 下降0.6%前月比2026年10月
- 公開された売上
- 非公開
- 保有製品の公開収益なし
訪問
プロダクト
| プロダクト | 月間訪問 · 10月 | 操作 |
|---|---|---|
| Fierce BiotechFierce Biotechのニュースと報告 | 879.4K |
タイムライン
11月18日 · 4日前
Fierce Biotech reports Pfizer's deal for Starna's CAR-T programs参照元&被リンク
Fierce Biotech reports that Pfizer agreed to a deal worth up to $2.6 billion for three preclinical autoimmune programs from Starna Therapeutics, including $330 million upfront.
11月17日 · 5日前
Fierce Biotech reports Marrow Therapeutics' launch and $173 million funding参照元&被リンク
Fierce Biotech reports that Marrow Therapeutics has launched with $173 million in funding. The funding will advance a preclinical therapy targeting sickle cell disease and beta thalassemia.
Fierce Biotech reports Isomorphic Labs' $5 billion Series C参照元&被リンク
Fierce Biotech reports that Isomorphic Labs raised $5 billion in a Series C, six months after securing $2.1 billion for its AI drug development platform.
Fierce Biotech reports Kyntra Bio scrapping its phase 2 cancer program参照元&被リンク
Fierce Biotech reports that Kyntra Bio, formerly FibroGen, scrapped its phase 2 prostate cancer ADC program after it failed to meet an efficacy threshold.
Fierce Biotech covers European biotech funding discussion at London Life Sciences Week参照元&被リンク
Fierce Biotech's coverage describes investors weighing Europe's biotech funding challenges and opportunities at its London Life Sciences Week event. The article asks whether 2027 could be Europe's year to shine.
11月13日 · 9日前
Fierce Biotech reports positive phase 2 results for Regeneron's baloncibart参照元&被リンク
Fierce Biotech reports that baloncibart met the primary endpoint in a phase 2 trial for POTS. Regeneron plans to launch a potentially pivotal study in 2027.
Fierce Biotech reports Rezera delaying its IPO参照元&被リンク
Fierce Biotech reports that Rezera delayed its public offering, citing market conditions. This is a later development of Fierce Biotech's earlier coverage of Rezera's IPO target.
Fierce Biotech reports Windward Bio's $225M IPO target参照元&被リンク
Fierce Biotech reports that Sanofi-backed Windward Bio has hit its $225M IPO target to advance its respiratory pipeline.
11月5日 · 17日前
Fierce Biotech covers Rezera's $181 million IPO target参照元&被リンク
Fierce Biotech reports that Rezera, formerly NodThera, is targeting $181 million in IPO proceeds to fund a phase 3 trial for its lead NLRP3 inhibitor.
Fierce Biotech covers Evommune's $1.1B deal with Hinova Pharma参照元&被リンク
Fierce Biotech reports that Evommune signed a deal worth up to $1.1 billion with Hinova Pharmaceuticals to develop VAV1-targeting molecular glue degraders.
よくある質問と根拠データ
- FierceBiotech はこれまでにどのような製品を作っていますか?
- EarlyLore では FierceBiotech の独立系ソフトウェア製品 1 件(現在稼働中 1 件)を追跡しており、代表的な製品に Fierce Biotech があります。
- FierceBiotech の運営プロダクト全体のWebトラフィック規模はどのくらいですか?
- トラフィック推計のある独自ドメインを集計すると、FierceBiotech のポートフォリオは各サイト最新観測月の合計で月間 879.4K 訪問に達します。共有ホスティングやストア専用ページは合算対象から除かれます。
個人開発者向け関連リサーチガイド